Impact of esomeprazole and vonoprazan on the antiplatelet effect of clopidogrel and prasugrel, with reference to CYP2C19 genotypes
Not Applicable
- Conditions
- Ischemic heart disease and upper gastrointestinal bleeding.
- Registration Number
- JPRN-UMIN000019901
- Lead Sponsor
- The First Department of Medicine and the Center for Clinical Research at Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria are any underlying disease, smoking habit, past or present H. pylori infection, and habitual use of any medicine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is antiplatelet effect with the six regimens as assessed by P2Y12 assay using Verify Now System (Accumetrics, Inc., San Diego, USA) on Day7 of each regimen.
- Secondary Outcome Measures
Name Time Method